• Q1 2026 consolidated revenue KRW 32.5B (vs full year 2025 KRW 118.3B), operating profit KRW 6.3B, net profit KRW 41.3B (swing from net loss of KRW 87.5B in 2025 due to equity method gains)
• On March 12, 2026, the company cancelled 650,000 treasury shares as part of shareholder return policy
• The company has paid annual cash dividends since FY2020 (18th term) and plans to maintain stable dividend policy
• Ongoing patent infringement lawsuit by Rapigen Inc. (claim amount KRW 100.2B) – contingent liability risk
• Q1 2026 R&D expenses KRW 4.39B (13.48% of sales); new product launches including Vcheck U3 urine analyzer
• Consolidated debt ratio 4.4% (debt KRW 67.7B vs equity KRW 1.54T) – very low financial leverage